학술논문
索拉非尼治疗晚期肝细胞性肝癌的耐受性研究 / Tolerance of sorafenib in the treatment of advanced hepatocellular carcinoma
Document Type
Academic Journal
Author
Source
中华实验外科杂志 / CHINESE JOURNAL OF EXPERIMENTAL SURGERY. 27(10):1535-1536
Subject
Language
Chinese
ISSN
1001-9030
Abstract
目的 探讨索拉非尼在临床治疗晚期原发性肝癌中的耐受性、安全性及相关疗效.方法 对2008年11月至2009年11月间于我院诊断晚期原发性肝癌接受索拉非尼治疗的患者的相关临床数据进行分析,应用t检验及x2检验.结果 本研究16例患者,平均生存时间12.37个月.治疗前Child评分A级者11例、B级3例、C级2例;治疗3个月后,治疗前A级患者中4例进展至B级,B级中2例进展至C级.治疗前MELD平均值为5.31,治疗后1个月为5.38(P＞0.05),治疗后3个月为6.67(P＞0.05).治疗前Child A级的患者平均总生存期为14.00个月,B/C级患者为8.80个月(P＞0.05).根据BCLC分期,B级患者的平均生存时间为13.70个月,C/D级患者的平均生存时间为10.17个月.结论 索拉非尼治疗可延长晚期肝细胞性肝癌的总生存期,并且在不同肝功能状态的患者中均耐受性良好.
Objective To evaluate the tolerance, safety and curative effect of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods The clinical data of 16 cases of patients who had been diagnosed as unresectable HCC from November 2008 to November 2009 were retrospectively analyzed. Results The average survival time was 12.37 months. When stratified according to Child-Pugh score, there were 11,3 and 2 patients in grades A, B, C respectively before the therapy. One month later, one patient of grade A was transformed to B, and one of grade B to C. Three months later, 4patients of grade A was transformed to B, and 2 of grade B to C. The average model for end-stage liver disease ( M ELD) score before the therapy was 5.31, and that was 5.38 ( P ＞ 0. 05 ) one month later and 6.67(P ＞ 0.05 ) three months later. The average survival time of Child A and Child B/C was 14.00 and 8.80months respectively ( P ＞ 0.05). If stratified according to BCLC grade, the average survival time in grade B group and grade C/D group was 13.70 and 9.50 months respectively. Conclusion Sorafenib may prolong the total survival time of patients with advanced HCC, and it was well tolerated in patients with different states of liver function.
Objective To evaluate the tolerance, safety and curative effect of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods The clinical data of 16 cases of patients who had been diagnosed as unresectable HCC from November 2008 to November 2009 were retrospectively analyzed. Results The average survival time was 12.37 months. When stratified according to Child-Pugh score, there were 11,3 and 2 patients in grades A, B, C respectively before the therapy. One month later, one patient of grade A was transformed to B, and one of grade B to C. Three months later, 4patients of grade A was transformed to B, and 2 of grade B to C. The average model for end-stage liver disease ( M ELD) score before the therapy was 5.31, and that was 5.38 ( P ＞ 0. 05 ) one month later and 6.67(P ＞ 0.05 ) three months later. The average survival time of Child A and Child B/C was 14.00 and 8.80months respectively ( P ＞ 0.05). If stratified according to BCLC grade, the average survival time in grade B group and grade C/D group was 13.70 and 9.50 months respectively. Conclusion Sorafenib may prolong the total survival time of patients with advanced HCC, and it was well tolerated in patients with different states of liver function.